Grant of Share Options & PDMR dealing26th November 2020 - 9:36 am
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company (“Ordinary Shares”) to Directors, employees and consultants representing 3.8% of ImmuPharma’s Ordinary Shares and total voting rights (the “Options”). ImmuPharma currently has 250,221,297 Ordinary Shares in issue.
Upon the recommendation of the Company’s remuneration committee, the Company has granted the Options pursuant to the Company’s Share Option Plan which was adopted on 30 March 2017 (the “2017 Plan”).
The exercise price for the Options is 20p being a 54% premium to the closing middle market share price of 13p on 25 November 2020. The Options will vest after three years and are exercisable between three and ten years from the date of grant.
The amount of Options granted to the Directors are summarised in the following table: